О роли цитокинов при бронхиальной астме

бронхиальная астма , цитокины , конденсат выдыхаемого воздуха , интерлейкины

1. Barnes P.J. The cytokine network in asthma and chronic obstructive pulmonary disease. J. Clin. Invest. 2008; 118 (11): 3546-3556.

2. Barnes P.J. Cytokine-directed therapies for the treatment of chronic airway diseases. Cytokine Growth Factor Rev. 2003; 14 (6): 511-522.

3. Царегородцева Т.М., Серова Т.И. Цитокины в гастроэнтерологии. М.: Анахарсис; 2003.

4. Fischer H.G., Frosch S., Reske K. et al. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 1988; 141: 3882-3888.

5. Schleimer R.P., Sterbinsky C.A., Kaiser C.A. et al. Interleukin-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM1. J. Immunol. 1992; 148: 1086-1092.

6. Дранник Г.Н. Клиническая иммунология и аллергология. М.: Мед. информ. агентство; 2003.

7. Steinke J.W., Borish L. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir. Res. 2001; 2: 66-70.

8. Wills-Karp M., Luyimbazi J., Xu X. et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261.

9. Kawaguchi M., Adachi M., Oda N. et al. IL-17 cytokine family. J. Allergy Clin. Immunol. 2004; 114: 1265-1273.

10. Gately M.K., Renzetti L.M., Magram J. et al. The interleukin-12 / interleukin-12-receptor system: role in normal and pathologic immune responses. Ann. Rev. Immunol 1998; 16: 495-521.

11. Bryan S., O`Connor B.J., Matti S. et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response. Lancet 2000; 356: 2149-2153.

12. Kim T.S., DeKruyff R.H., Rupper R. et al. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J. Immunol. 1997; 158: 4137-4144.

13. Lack G., Bradley K.L., Hamelmann E. et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. J. Immunol. 1996; 157: 1432-1439.

14. Gratzl S., Palca A., Schmitz M., Simon H.U. Treatment with IFN-α in corticosteroid-unresponsive asthma. J. Allergy Clin. Immunol. 2000; 105: 1035-1036.

15. Boguniewicz M., Martin R.J., Martin D. et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J. Allergy Clin. Immunol. 1995; 95 (1, pt. 1): 133-135.

16. White J.R., Lee J.M., Dede K. et al. Identification of potent, selective nonpeptide CC chemokine receptor-3 antagonist that inhibits eotaxin, eotaxin-2, and monocyte chemotactic protein4induced eosinophil migration. J. Biol. Chem. 2000; 275: 36626-36631.

17. Rossi D., Zlotnik A. The biology of chemokines and their receptors. Ann. Rev. Immunol. 2000; 18: 217-242.

18. Gutierrez-Ramos J.C., Lloyd C., Kapsenberg M.L. et al. Nonredundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung. Immunol. Rev. 2000; 177: 31-42.

19. Wilson J. The bronchial microcirculation in asthma. Clin. Exp. Allergy 2000; 30 (suppl. 1): 51-53.

20. Feltis B.N., Wignarajah D., Zheng L. et al. Increased vascular endothelial growth factor and receptors: relationship to angiogenesis in asthma. Am. J. Respir. Crit. Care Med. 2006; 173: 1201-1207.

21. Delgado J., Barranco P., Quirce S. Оbesity and asthma. J. Invest. Allergol. Clin. Immunol. 2008; 18 (6): 420-425.

22. Dixon A.E., Raymond D.M., Suratt B.T. et al. Lower airway disease in asthmatics with and without rhinitis. Lung 2008; 186 (6): 361-368.

23. Goleva E., Hauk P.J., Hall C.F. et al. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J. Allergy Clin. Immunol. 2008; 122 (3): 550-559.

24. Bayley D.L., Abusriwil H., Ahmad A., Stockley R.A. Validation of assays for inflammatory mediators in exhaled breath condensate. Eur. Respir. J. 2008; 31 (5): 943-948.

25. Horváth I., Hunt J., Barnes P.J. On behalf of the ATS / ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur. Respir. J. 2005; 26: 523-548.

26. Lasagna L., Peveri S., Pilotti E. et al. Inflammatory cytokines in exhaled breath condensate (EBC) of exacerbated COPD patients. Eur. Respir. J. 2008; 32 (52): 1105.

27. Robroeks C.M., van de Kant K.D., Jöobsis Q. et al. Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. Clin. Exp. Allergy 2007; 37 (9): 1303-1311.

28. Borrill Z.L., Roy K., Singh D. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J. 2008; 32: 472-486.

29. Matsunaga K., Yanagasima S., Ueshima K. et al. Airway cytokine expression measured by means protein array in exhaled breath condensate: Correlation with properties in asthmatic patients. Rinsho Byori 2007; 55 (4): 375-380.

30. Shahid S.K., Kharitonov S.A., Wilson N.M. et al. Increased interleukin-4 and decreased interferon-gamma in exhaled breath condensate of children with asthma. Am. J. Respir. Crit. Care Med. 2002; 165: 1290-1293.